Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals Inc (NQ: MIRM )

44.10 -0.63 (-1.41%)
Streaming Delayed Price Updated: 3:20 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Where Mirum Pharmaceuticals Stands With Analysts
Via Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
The Latest Analyst Ratings For Mirum Pharmaceuticals
Via Benzinga
11 Analysts Have This to Say About Mirum Pharmaceuticals
Via Benzinga
Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fell sharply during Wednesday’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Analyst Ratings for Mirum Pharmaceuticals
Via Benzinga
Earnings Outlook For Mirum Pharmaceuticals
Via Benzinga
Analyst Ratings for Mirum Pharmaceuticals
Via Benzinga
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic... 
Via Benzinga
Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to... 
Via Newsfile
Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Presents New Data at The Liver Meeting®
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Present New Data at The Liver Meeting®
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
7 Small-Cap Stocks That Get the Nod from Wall Street
Although small-cap stocks tend to be extremely risky, these compelling ideas just happen to get the nod from Wall Street analysts. 
Via InvestorPlace
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.